Global Diabetic Neuropathy Market Report 2022: Breakthrough Product Development to Shape the Industry Ahead –


DUBLIN–()–The “Global Diabetic Neuropathy Market, by Disorder, by Distribution Channel, and by Region – Forecast and Analysis 2022-2028” report has been added to from offer.

Global Diabetic Neuropathy Market was valued at USD 4.66 Billion in 2021, and it is projected to reach a value of USD 8.47 Billion by 2028, growing at a CAGR of 8.9% over the forecast period (2022 -2028).

Diabetic neuropathy is a condition that damages the nerves and is linked to high blood sugar. People who have had diabetes for a long time are more likely to develop nerve damage throughout their body, even if the symptoms of diabetic neuropathies could not be identified at an early stage. Despite the fact that diabetic neuropathy cannot be treated, it can be managed or prevented using a number of treatment techniques. Regulators are required to approve more therapeutic items and techniques related to the disease due to its complexity.

Both top-down and bottom-up approaches have been used to estimate and validate the size of the Global Diabetic Neuropathy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: Major market players have been identified through secondary research and their market shares in respective regions have been determined through primary and secondary research. This whole procedure includes the study of annual and financial reports of the main market players and in-depth interviews to obtain key information from industry leaders such as CEOs, VPs, directors and managers. marketing. All percentage shares are divided and the breakdowns have been determined using secondary sources and verified using primary sources. All the possible parameters that affect the markets covered in this research study have been considered, thoroughly investigated, verified through primary research and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The global diabetic neuropathy market segmentation is based on disorder, distribution channel, and region. Based on the disorder, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Based on distribution channels, the market is segmented into hospitals, clinics, retail pharmacies and online pharmacies. Based on region, the global diabetic neuropathy market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.


Due to the increased incidence of diabetes over the forecast period, the growth rate of the global diabetic neuropathy market would be higher. Additionally, obesity, coronary heart disease, diabetic neuropathy, and other sugar management issues are believed to be some of the factors driving the growth of the market. Increasing urbanization, which encourages sedentary behaviors like carbohydrate consumption and minimal exercise, is also impacting the boom in the market.


Some of the barriers to market expansion include rising cost of diabetic neuropathy treatments, widening selection of complementary therapies, and other factors. Strict regulations, product recalls, delays in Food and Drug Administration certifications, and other similar issues may further hamper the growth of this industry.

Market trends

High-tech products will be created in the coming year for more effective treatment of diabetic neuropathy. The companies are putting their efforts into the development of talc, transdermal patches and mouthwashes, among others. To solve the problems with surgical drugs, manufacturers have come up with advanced technologies for drug delivery, such as syringe-less techniques.

Companies cited

  • Johnson & Johnson (USA)

  • Boehringer Ingelheim GmbH (Germany)

  • NeuroMetrix, Inc (USA)

  • Eli Lilly and Company (USA)

  • GlaxoSmithKline plc (UK)

  • Lupine Limited (India)

  • Pfizer Inc (USA)

  • Astellas Pharma Inc (Japan)

  • Glenmark Pharmaceuticals Ltd (India)

  • Arbor Pharmaceuticals, LLC (USA)

  • Depomed, Inc (USA)

For more information on this report, visit


Comments are closed.